RxDoctor Payments DataLook up a doctor →

Adam Stys, MD

Interventional Cardiology · Sioux Falls, SDNPI 1083656821

Payments from drug & device makers

$154,896in general payments, 2019–2025

Across 308 payments — averaging $502.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endotronix, Inc.$148K
  • Abbott$2K
  • Medtronic$1K
  • Abiomed$903
  • Acist Medical Systems, Inc.$546
  • Johnson & Johnson$473
  • plus $2K from 29 others

What the payments were for

  • Travel & lodging$1,09015%
  • Food & beverage$6,23385%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$734,312
Medicare patients
3,192
Services billed
10,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban815$719,161
XareltoRivaroxaban391$328,287
Repatha SureclickEvolocumab98$60,796
Praluent PenAlirocumab68$34,017
BrilintaTicagrelor60$32,078
EntrestoSacubitril/Valsartan28$28,489
MultaqDronedarone Hcl15$14,119
Metoprolol Succinate992$11,748
JardianceEmpagliflozin17$11,149
Ranolazine ErRanolazine70$9,306
Repatha SyringeEvolocumab16$8,271
Rosuvastatin Calcium585$7,361
Diltiazem 24hr Er (Cd)Diltiazem Hcl193$6,857
Dabigatran EtexilateDabigatran Etexilate Mesylate19$6,188
Ezetimibe179$6,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$719,161815 claims
Johnson & JohnsonXarelto$473$328,287391 claims
AstraZenecaBrilinta$240$32,07860 claims
Sanofi-aventis U.S. LLCMultaq$12$14,11915 claims
Boehringer IngelheimJardiance$11$11,14917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in South Dakotaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →